Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents
PLOS One · 2026
DOI: 10.1371/journal.pone.0356596 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Min Seok Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Macular Degeneration, Angiogenesis Inhibitors, Eye Hemorrhage. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University Bundang Hospital, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Background
Intraocular hemorrhage is a vision-threatening complication in patients with exudative age-related macular degeneration (AMD) receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapy. We aimed to compare the risk of intraocular hemorrhage requiring vitrectomy among patients with exudative AMD treated with ranibizumab, aflibercept, or brolucizumab. Methods and findings This nationwide retrospective cohort study used claims data from the Korean National Health Insurance Review and Assessment Service (May 2014–April 2023). Korean patients aged 40 years or older with newly diagnosed exudative AMD who initiated anti-VEGF therapy and had no history of intraocular hemorrhage were included. The primary outcome was intraocular hemorrhage requiring vitrectomy after anti-VEGF initiation. Time-to-event analyses using Cox proportional hazards regression estimated hazard ratios (HRs) and 95% CIs; Kaplan–Meier curves showed cumulative incidence probability, and logistic regression provided complementary risk estimates. Among 75,812 patients, 1,128 (1.5%) experienced intraocular hemorrhage requiring vitrectomy. Compared with ranibizumab, the adjusted risk was higher with brolucizumab (HR, 1.83; 95% CI, 1.18–2.83; P = .007) and aflibercept (HR, 1.31; 95% CI, 1.14–1.49; P < .001). Logistic regression similarly showed higher odds with aflibercept versus ranibizumab (adjusted odds ratio, 1.32; 95% CI, 1.16–1.51; P < .001). Patients with hemorrhage received fewer anti-VEGF injections in the first year than those without hemorrhage (3.15 ± 1.87 vs 4.01 ± 1.85; P < .001).
Conclusion
In this large nationwide cohort, intraocular hemorrhage requiring vitrectomy after anti-VEGF therapy for exudative AMD was rare but occurred more frequently with brolucizumab and aflibercept than with ranibizumab. Although unlikely to be the primary determinant of anti-VEGF selection, these findings provide adjunctive safety information that may be considered when counseling and monitoring selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- Data research, Samil Pharm Co. LTD, Seoul, Korea.
ORCID-Profile: Se Joon Woo
Förderung
- Seoul National University Bundang Hospital
- Korea Health Industry Development Institute
Zitieren
APA
Kim, M. S., Nam, S., Lee, J., & Woo, S. J. (2026). Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents. PLOS One. https://doi.org/10.1371/journal.pone.0356596
Vancouver
Kim MS, Nam S, Lee J, Woo SJ. Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents. PLOS One. 2026. doi:10.1371/journal.pone.0356596
BibTeX
@article{Kim2026,
author = {Kim, Min Seok and Nam, Seonghee and Lee, Jeongwoo and Woo, Se Joon},
title = {Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0356596}
}
EUVIMED